Bad Things Come In Threes At Viatris As Firm Issues Another Labelling Recall
Viatris Recalls Third Insulin Product This Year Over Missing Labels
Executive Summary
Viatris has recalled a batch of its unbranded insulin glargine injector pens after a manufacturing error meant some pens might be missing labels. It is the third time this year the firm has had to recall an insulin product due to a labelling error.
You may also be interested in...
Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar
A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.
Viatris Recalls Semglee Batch Citing Missing Labels
Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products.
Hexarad: Building A Professional Community Of Remote-Working Radiologists
British teleradiology provider Hexarad has shot from strength to strength in recent years, launching two different programs and opening up opportunities for its network of radiologists to continue supporting the National Health Service while working abroad. Company CEO Farzanah Rahman, one of In Vivo’s 2023 Rising Leaders, discussed Hexarad’s expansion, its values and the myth of the sole leader.